Search results
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 1 day agoSource: Takeda Pharmaceutical. Conclusion Takeda is one of the leaders in the global gastrointestinal and cancer therapeutics markets, which is...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed...
Benzinga· 17 hours agoThe confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant...
NBC 17 Raleigh· 7 days ago− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen ...
YHB Investment Advisors Inc. Trims Stake in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 6 days agoYHB Investment Advisors Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.7% during the 4th quarter, according to its most recent 13F filing with the Securities ...
Wealthspan Partners LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 7 days agoWealthspan Partners LLC boosted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities and ...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening...
Morningstar· 3 days agoAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming ...
Galapagos (NASDAQ:GLPG) Receives “Equal Weight” Rating from Morgan Stanley
ETF DAILY NEWS· 21 hours agoGalapagos (NASDAQ:GLPG – Get Free Report)‘s stock had its “equal weight” rating reissued by equities research analysts at Morgan Stanley in a research report issued to clients and investors ...
Tufton Capital Management Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 15 hours agoTufton Capital Management decreased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the ...